WO2000070041A1 - Mixed-bed solid phase and its use in the isolation of nucleic acids - Google Patents
Mixed-bed solid phase and its use in the isolation of nucleic acids Download PDFInfo
- Publication number
- WO2000070041A1 WO2000070041A1 PCT/US2000/012954 US0012954W WO0070041A1 WO 2000070041 A1 WO2000070041 A1 WO 2000070041A1 US 0012954 W US0012954 W US 0012954W WO 0070041 A1 WO0070041 A1 WO 0070041A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid phase
- solution
- mixed
- silica
- bed
- Prior art date
Links
- 239000007790 solid phase Substances 0.000 title claims abstract description 524
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 302
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 302
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 302
- 238000002955 isolation Methods 0.000 title description 51
- 239000000203 mixture Substances 0.000 claims abstract description 177
- 238000000034 method Methods 0.000 claims abstract description 159
- 239000013612 plasmid Substances 0.000 claims abstract description 97
- 239000000356 contaminant Substances 0.000 claims abstract description 70
- 239000012149 elution buffer Substances 0.000 claims abstract description 53
- 238000010828 elution Methods 0.000 claims abstract description 18
- 230000003321 amplification Effects 0.000 claims abstract description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 11
- 230000002255 enzymatic effect Effects 0.000 claims abstract 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 651
- 239000000377 silicon dioxide Substances 0.000 claims description 312
- 239000002245 particle Substances 0.000 claims description 212
- 239000006249 magnetic particle Substances 0.000 claims description 176
- 230000005291 magnetic effect Effects 0.000 claims description 112
- 238000005349 anion exchange Methods 0.000 claims description 64
- 239000000463 material Substances 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 58
- 239000002158 endotoxin Substances 0.000 claims description 54
- 239000012071 phase Substances 0.000 claims description 42
- 238000005342 ion exchange Methods 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 230000003196 chaotropic effect Effects 0.000 claims description 32
- 238000005119 centrifugation Methods 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 14
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 229920000936 Agarose Polymers 0.000 claims description 12
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 7
- 229960001340 histamine Drugs 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 238000010908 decantation Methods 0.000 claims description 3
- SGKDAFJDYSMACD-UHFFFAOYSA-N dimethoxy(propyl)silane Chemical compound CCC[SiH](OC)OC SGKDAFJDYSMACD-UHFFFAOYSA-N 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 6
- 239000006167 equilibration buffer Substances 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 239000013611 chromosomal DNA Substances 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 213
- 108020004414 DNA Proteins 0.000 description 153
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 68
- 239000006166 lysate Substances 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 48
- 239000000523 sample Substances 0.000 description 40
- 239000000499 gel Substances 0.000 description 30
- 239000003480 eluent Substances 0.000 description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 239000011543 agarose gel Substances 0.000 description 22
- 238000009739 binding Methods 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 229960005542 ethidium bromide Drugs 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 16
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 238000011534 incubation Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 238000000926 separation method Methods 0.000 description 15
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000006386 neutralization reaction Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 238000011109 contamination Methods 0.000 description 11
- 125000000524 functional group Chemical group 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 229910052742 iron Inorganic materials 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000013068 control sample Substances 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 238000002123 RNA extraction Methods 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- -1 lymph Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108091006522 Anion exchangers Proteins 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
- 238000007885 magnetic separation Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002902 bimodal effect Effects 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000007399 DNA isolation Methods 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108010072542 endotoxin binding proteins Proteins 0.000 description 3
- 239000000383 hazardous chemical Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000009616 inductively coupled plasma Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000000696 magnetic material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000005372 silanol group Chemical group 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- ZLDHYRXZZNDOKU-UHFFFAOYSA-N n,n-diethyl-3-trimethoxysilylpropan-1-amine Chemical compound CCN(CC)CCC[Si](OC)(OC)OC ZLDHYRXZZNDOKU-UHFFFAOYSA-N 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000013077 target material Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000011050 LAL assay Methods 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241000239220 Limulus polyphemus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- SAQSTQBVENFSKT-UHFFFAOYSA-M TCA-sodium Chemical compound [Na+].[O-]C(=O)C(Cl)(Cl)Cl SAQSTQBVENFSKT-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012629 conventional elemental analysis Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000642 polymer Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229910021489 α-quartz Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
- B01J47/02—Column or bed processes
- B01J47/04—Mixed-bed processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
Definitions
- This invention relates generally to materials and methods for isolating nucleic acids, such as plasmid DNA, chromosomal DNA, total RNA, mRNA, viral DNA, viral RNA, or RNA/DNA hybrids from contaminants, such as proteins, lipids, cellular debris, or other nucleic acids.
- This invention relates, particularly, to solid phases, including magnetic or non-magnetic matrices and chromatographic stationary phases, which bind to a target nucleic acid under one set of solution conditions and release the target nucleic acid under another set of solution conditions. More particularly, this invention relates to mixed-bed solid phases comprising at least two different solid phases, wherein each solid phase in the mixture binds to and releases a target nucleic acid under different conditions.
- nucleic acids used in the techniques be substantially free of contaminants capable of interfering with such processing or analysis procedures.
- contaminants generally include substances that block or inhibit chemical reactions, (e.g. substances that hybridize to nucleic acids, or substances that block or inhibit enzymatically catalyzed reactions, and other types of reactions used in molecular biological techniques), substances that catalyze the degradation or depolymerization of a nucleic acid or other biological material of interest, or substances which block or mask detection of the nucleic acid of interest.
- Substances of this last type can block or mask by providing a "background" indicative of the presence in a sample of a quantity of a nucleic acid of interest, (also referred to herein as a "target nucleic acid”) when the nucleic acid of interest is not, in fact, present in the sample.
- Contaminants also include macromolecular substances from the in vivo or in vitro medium from which a target nucleic acid is isolated, macromolecular substances such as enzymes, other types of proteins, polysaccharides, or polynucleotides, as well as lower molecular weight substances, such as lipids, low molecular weight enzyme inhibitors, oligonucleotides, or non-target nucleic acids.
- Contaminants can also be introduced into a target biological material from chemicals or other materials used to isolate the material from other substances. Common contaminants of this last type include trace metals, dyes, and organic solvents.
- target nucleic acid which is sufficiently free of contaminants for molecular biological applications, is complicated by the complex systems in which the target nucleic acid is typically found.
- Such systems e.g., cells from tissues, cells from body fluids such as blood, lymph, milk, urine, feces, semen, or the like, cells in culture, agarose or polyacrylamide gels, or solutions in which target nucleic acid amplification has been carried out
- Such systems typically include significant quantities of contaminants from which the target nucleic acid of interest must be isolated before being used in a molecular biological procedure.
- Endotoxins are particularly problematic contaminants in preparations of nucleic acids isolated from gram-negative bacilli.
- an endotoxin is a lipopolysaccharide material found in the cell wall of most such bacilli, including Escherichia coli ("E. coli ").
- E. coli Escherichia coli
- endotoxins are released into the lysate produced thereby.
- Endotoxin contamination in a nucleic acid sample can adversely limit the utility of the sample, particularly in applications, which are sensitive to such contamination.
- Endotoxins have also been found to be toxic to primary human cells, such as primary human skin fibroblasts and primary human melanoma cells, in the presence of entry-competent adenovirus particles. Cotten, M. et al. 1994, Gene Therapy 1 :239-246. Endotoxins have also been shown to produce striking pathophysiological reactions when introduced into animals, including high fever, vasodilation, diarrhea and, in extreme cases, fatal shock. Morrison, David C. 1987, Ann. Rev. Med. 38:417-32.
- Endotoxins are not readily separated from nucleic acids, particularly from plasmid DNA. Endotoxins tend to form micelles, which have a similar density, size, and charge distribution to plasmid DNA on the outer surface of the endotoxin micelles. As a result, endotoxins co-purify with nucleic acids, particularly with plasmid DNA, in most nucleic acid isolation procedures used today. For example, endotoxins appear in the same band as the DNA-ethidium bromide complex in the cesium chloride gradients used to separate plasmid DNA from other materials in a bacterial lysate. Endotoxins also co-migrate and co-elute with plasmid DNA from size exclusion and from anion exchange resins.
- RNA isolation protocols generally entail suspending the cells in a solution and using enzymes and/or chemicals, gently to lyse the cells, thereby releasing the DNA contained within the cells into the resulting lysate solution.
- DNA isolation protocols include measures for inhibition of ribonucleases and contaminants, including DNA, to be separated from the RNA.
- the DNA/ethidium bromide band is extracted therefrom and the plasmid DNA isolated from the ethidium bromide using butanol or other conventional means. See, e.g., Molecular Cloning, ed. by Sambrook et al. (1989), pub. by Cold Spring Harbor Press, pp. 1.42-1.50.
- the phenol/chloroform extraction step, or cesium chloride banding and ethidium bromide extraction step is generally followed by precipitation of the nucleic acid material remaining in the extracted aqueous phase by adding ethanol to that aqueous phase. The precipitate is typically removed from the solution by centrifugation, and the resulting pellet of precipitate is allowed to dry before being resuspended in water or a buffer solution for further processing or analysis.
- Ethanol (or isopropanol) precipitation must be employed to precipitate the DNA from a phenol/chloroform-extracted aqueous solution of DNA and remove residual phenol and chloroform from the DNA. Further, ethanol (or isopropanol) precipitation is required to remove some nucleoside triphosphate and short (i.e., less than about 30 bases or base pairs) single or double-stranded oligonucleotide contaminants from the DNA. Moreover, under the best circumstances such methods produce relatively low yields of isolated nucleic acid material, and the isolated nucleic acid material is contaminated with impurities. Cesium chloride gradients take time to form, requiring at least four hours of spin time in even the fastest, most modern centrifuges.
- Ethidium bromide required for banding of plasmid or chromosomal DNA in such gradients, is a mutagen. Also, when cesium chloride banding is used to isolate plasmid DNA from bacterial lysates without any preceding or succeeding protein extraction step, such as a phenol/chloroform extraction, the plasmid DNA isolated therewith has been found to be highly contaminated with endotoxins. See, e.g. Cotten, et al., Gene Tlierapy (1994) 1 :239-146, at 240 [Table 1].
- One of the first solid phases developed for use in isolating nucleic acids was a specialized resin of porous silica gel particles designed for use in high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- the surface of the porous silica gel particles was functionalized with anion-exchangers, which could exchange with plasmid DNA under certain salt and pH conditions. See, e.g. U.S. Pat. No's: 4,699,717, and 5,057,426.
- Machrey-Nagel Co. D ⁇ ren, Germany
- Machrey-Nagel one of the first companies to provide HPLC columns packed with such anion-exchange silica gel particles. Machrey-Nagel continues to sell such columns today. See, e.g.
- NUCLEOGEN ® 4000-7DEAE Information about NUCLEOGEN ® 4000-7DEAE in product information downloaded from the Machrey- Nagel homepage on the Internet on 6/12/98, at http://www.machrey-nagel.com.
- Each such column was designed so that plasmid DNA bound thereto is eluted in an aqueous solution containing a high concentration of a highly corrosive salt (e.g. plasmid DNA is eluted from the NUCLEOGEN , 4000-7DEAE column in 6 M urea).
- Each such column had to be washed thoroughly between each isolation procedure to remove the corrosive salt and contaminants bound to the column with the DNA from the system.
- the nucleic acid solution eluted therefrom also had to be processed further to remove the corrosive salt therefrom before it could be used in standard molecular biology techniques, such as cloning, transformation, digestion with restrictive enzymes, or amplification.
- silica-based solid phase separation systems have been developed since the early HPLC systems described above.
- Modern silica-based systems utilize controlled pore glass, filters embedded with silica particles, silica gel particles, resins comprising silica in the form of diatomaceous earth, glass fibers or mixtures of the above.
- Each modern silica-based solid phase separation system is configured to reversibly bind nucleic acid materials when placed in contact with a medium containing such materials in the presence of chaotropic agents.
- Such solid phases are designed to remain bound to the nucleic acid material while the solid phase is exposed to an external force such as centrifugation or vacuum filtration to separate the matrix and nucleic acid material bound thereto from the remaining media components.
- the nucleic acid material is then eluted from the solid phase by exposing the solid phase to an elution solution, such as water or an elution buffer.
- an elution solution such as water or an elution buffer.
- silica-based resins designed for use in centrifugation and/or filtration isolation systems. See, e.g. WizardTM DNA purification systems products from Promega Corporation (Madison, Wisconsin, U.S.A.); or the QiaPrepTM DNA isolation systems from Qiagen Corp. (Santa Clarita, California, U.S.A.)
- Magnetically responsive particles formerly used to isolate and purify polypeptide molecules such as proteins or antibodies, have also been developed for use as solid phases in isolating nucleic acids.
- Several different types of magnetically responsive particles designed for isolation of such materials are described in the literature, and many of those types of particles are available from commercial sources. Such particles generally fall into either of two categories, those designed to reversibly bind nucleic acid materials directly, and those designed to reversibly bind nucleic acid materials through an intermediary.
- silica based porous particles designed to reversibly bind directly to DNA such as MagneSilTM particles to be made commercially available from Promega Corporation, or BioMag magnetic particles available from PerSeptive Biosystems.
- mRNA nucleic acid
- PolyATract ® Series 9600TM mRNA Isolation System from Promega Corporation
- Pro ActiveTM line of streptavidin coated microsphere particles from Bangs Laboratories (Carmel, Indiana, U.S.A.).
- Both of these latter two systems employ magnetically responsive particles with avidin subunits covalently attached thereto, and streptavidin with an oligo dT moiety covalently attached thereto.
- the streptavidin-oligo dT molecules act as intermediaries, hybridizing to the poly A tail of mRNA molecules when placed into contact therewith, then binding to the particles through a releasable streptavidin-avidin bond.
- the indirect binding magnetic separation systems for nucleic acid isolation or separation all require at least three components, i.e. magnetic particles, an intermediary, and a medium containing the nucleic acid material of interest.
- the intermediary/nucleic acid hybridization reaction and intermediary/particle binding reaction often require different solution and/or temperature reaction conditions from one another.
- Each additional component or solution used in the nucleic acid isolation procedure adds to the risk of contamination of the isolated end product by nucleases, metals, and other deleterious substances.
- Various types of magnetically responsive silica based particles have been developed for use as solid phases in direct or indirect nucleic acid binding isolation methods.
- One such particle type is a magnetically responsive glass bead, preferably of a controlled pore size. See, e.g.
- Magnetic Porous Glass (MPG) particles from CPG, Inc. (Lincoln Park, New Jersey, U.S.A.); or porous magnetic glass particles described in U.S. Pat. No.'s 4,395,271 ; 4,233,169; or 4,297,337.
- Nucleic acid material tends to bind very tightly to glass, however, that it can be difficult to remove once bound thereto. Therefore, elution efficiencies from magnetic glass particles tend to be low compared to elution efficiencies from particles containing lower amounts of a nucleic acid binding material such as silica.
- Another type of magnetically responsive particle designed for use as a solid phase in direct binding and isolation of nucleic acids, particularly DNA, is a particle comprised of agarose embedded with smaller ferromagnetic particles and coated with glass. See, e.g. U.S. Patent 5,395,498.
- a third type of magnetically responsive particle designed for direct binding and isolation of nucleic acids is produced by incorporating magnetic materials into the matrix of polymeric silicon dioxide compounds. See, e.g. German Patent No. DE 43 07 262 Al . The latter two types of magnetic particles, the agarose particle and the polymeric silicon dioxide matrix, tend to leach iron into a medium under the conditions required to bind nucleic acid materials directly to each such magnetic particle.
- Silica-based solid phase nucleic acid isolation systems are quick and easy to use and do not require the use of corrosive or hazardous chemicals.
- such systems are ineffective at isolating nucleic acids from contaminants, such as endotoxins, which tend to bind to and elute from such solid supports under the same conditions as nucleic acids. See, e.g. Cotten, Matt et al. Gene Therapy (1994) 1:239- 246.
- nucleic acid isolation systems have been developed in which a nucleic acid solution containing proteins is pretreated with proteases to digest at least some of the proteins contained therein prior to isolation of the nucleic acid using a silica- based solid support of the type described above. See, e.g., QiaAmpTM Blood Kit provided by QIAGEN Inc. (Santa Clarita, California), which utilizes protease; and Wizard ® Plus SV Minipreps DNA Purification System provided by Promega Corp. (Madison, Wisconsin), which utilizes an alkaline protease.
- pre- treatment systems require the introduction of one contaminant into a mixture to digest another contaminant.
- Carry-over proteases can limit the utility of nucleic acids isolated using such modified silica-based systems at least as much as nucleic acid samples contaminated with the proteins the proteases are introduced to digest. Specifically, given the proper solution conditions, proteases in a nucleic acid solution will digest any proteins introduced into the solution, including enzymes introduced therein to modify, cut, or transcribe the nucleic acid contained therein for downstream processing or analysis. Protease addition, incubation and removal steps also drive up the cost of nucleic acid isolation, costing time and money compared to isolation systems with no such additional steps.
- each solid phase used therein has a substantially uniform surface composition designed to bind to a nucleic acid of interest, in the form of a silica or silica gel surface, or in the form of a silica gel or polymer surface modified with chemical groups exhibiting anion exchanger activities.
- Bimodal and multimodal systems have also been developed, in which multiple columns each of which contains a solid phase modified with a different chemical group from the other columns in the system (e.g., Wheatley J. B., J Chromatogr. (1992) 603: 273), or in which a single column is used with a single solid phase with at least two different chemical groups (e.g., Patent '680; Little, E. L.
- Each of the chemical groups on the surface of the solid supports in the single column or multicolumn multimodal systems is configured to bind to different materials in whatever substrate is introduced into the system. Only a few such bimodal or multimodal column chromatography systems have been developed specifically for nucleic acid isolation (see, e.g. U.S. Pat. No. 5,316,680). Surface group combinations used in such solid phase systems include reverse phase, ion exchange, size exclusion, normal phase, hydrophobic interaction, hydrophihc interaction, and affinity chromatography. Such systems are designed such that only one of the surface groups binds a target species, such as a nucleic acid, while the other surface group(s) bind to and remove one or more non-target species in a mixture.
- the bimodal and multimodal systems are far from simple, efficient alternatives to conventional organic or resin methods of nucleic acid isolation described above.
- Multi-column systems are inherently complex to run, as each column has requires a unique set of mobile phase conditions to bind and/or release the desired target or non-target species bound to the stationary solid phase of the system.
- Non-target species tend to block adjacent functional groups configured to bind to the target species, thus adversely affecting overall yield.
- all the bimodal or multimodal systems are only designed to separate a target species from other species for which functional groups have affinity. Materials and methods are needed which can quickly, safely, and efficiently isolate target nucleic acids which are sufficiently free of contaminants, particularly endotoxins, to be used in molecular biology procedures.
- the present invention addresses the need for materials and methods which provide a rapid and efficient means for isolating target nucleic acids from any mixture of target nucleic acids and contaminants, including lysates of gram-negative bacteria, thereby providing purified nucleic acids which can be used in a variety of biological applications, including transfection of cultured cells and in vivo administration of nucleic acids to organisms.
- BRIEF SUMMARY OF THE INVENTION Briefly, in one aspect, the present invention is a mixed-bed solid phase designed for use in isolating a target nucleic acid from a mixture comprising the target nucleic acid and at least one contaminant. In a preferred practice, multiple contaminants are included in the mixture.
- the mixed-bed solid phase comprises at least two different solid phases, each of which has a capacity to bind and to release the target nucleic acid in the presence of different solution conditions.
- the mixed-bed solid phase of the present invention preferably comprises a first solid phase and a second solid phase, wherein: the first solid phase has a capacity to bind to the target nucleic acid when combined with the mixture in the presence of a first solution, and a capacity to release the target nucleic acid bound thereto in the presence of a second solution; the second solid phase has a capacity to bind to the target nucleic acid when combined with the mixture in the presence of the second solution, and a capacity to release the target nucleic acid bound thereto in the presence of the first solution; and the first solid phase and the second solid phase each have a capacity to release the target nucleic acid bound thereto in the presence of an elution buffer.
- the present invention is a mixed-bed solid phase for isolating a target nucleic acid from a mixture comprising the target nucleic acid and at least one contaminant, the mixed-bed solid phase comprising first silica magnetic particles and second silica magnetic particles, wherein:
- the first silica magnetic particles have a capacity to bind to the target nucleic acid when combined with the mixture in the presence of a first solution, and a capacity to release the target nucleic acid bound thereto in the presence of a second solution;
- the second silica magnetic particles have a capacity to bind to the target nucleic acid when combined with the mixture in the presence of the second solution, and a capacity to release the target nucleic acid bound thereto in the presence of the first solution;
- the first silica magnetic particles and the second silica magnetic particles all have the capacity to release the target nucleic acid bound thereto in the presence of an elution buffer.
- the first silica magnetic particles and second silica magnetic particles are either silica magnetic particles each comprising at least one ion exchange residue covalently attached thereto, or silica magnetic particles comprising a siliceous oxide coating and no anion exchange residue, respectively.
- the ion exchange residue is either an anion exchange residue, or an ion exchange residue which has a positive charge in the presence of the first or second solution, such that it can exchange with the target nucleic acid within that solution.
- the present invention is silica magnetic particles, comprising: a plurality of first silica magnetic particles, each of which comprises a first silica magnetic particle covalently attached to a diethylamino (DEA) anion exchange residue.
- DEA diethylamino
- Such DEA ion exchange silica magnetic particles are particularly suitable for use as one of the solid phases in the mixed-bed solid phase of the present invention described above, and in the methods of isolating a target nucleic acid of the present invention described below.
- the present invention is, also, a method of isolating a target nucleic acid from a mixture comprising the target nucleic acid and at least one contaminant, using a mixed-bed solid phase comprising a first solid phase and a second solid phase.
- This method comprises the steps of:
- This embodiment of the present invention preferably further comprises additional steps, wherein the mixed-bed solid phase is recombined and separated from the first solution and the second solution prior to being combined with the elution buffer in step (f).
- the methods and materials of the present invention can be used to isolate target nucleic acids including, but not limited to plasmid DNA, total RNA, amplified nucleic acids, and genomic DNA from a variety of contaminants, including but not limited to agarose and components of a bacteria, animal tissue, and blood cells other than the target nucleic acid.
- the mixed-bed solid phase and method of this invention enable one to isolate a variety of different types of target nucleic acids quickly and efficiently from a variety of difference substances, without the need to use hazardous chemicals (e.g. phenol, chloroform, ethidium bromide, or cesium chloride).
- hazardous chemicals e.g. phenol, chloroform, ethidium bromide, or cesium chloride.
- the first solid phase and second solid phase work more efficiently in the mixed-bed configuration of the present invention than either phase would if used to isolate a target nucleic acid alone, in tandem, or as separate functional groups of the same solid phase, for the following reasons.
- a mixed-bed configuration enables one to transfer the target nucleic acid back and forth from the first solid phase to the second solid phase, thereby, further isolating the target nucleic acid from contaminants associated therewith, with each transfer step.
- the solid phases When only one of the solid phases is used to isolate the target nucleic acid, considerably fewer of the contaminants are removed.
- the target nucleic acid When used in tandem, the target nucleic acid is only bound to and released from each solid phase once, leaving at least one contaminants i.e. the target nucleic acid mixture.
- the target nucleic acid When two different functional groups having different affinities for the target nucleic acid are provided on the same solid phase, the target nucleic acid is not as efficiently bound and released therefrom as it is transferred from one solid phase to another using the mixed-bed solid phase in the method of the present invention.
- the mixed-bed solid phase produces surprising and unexpected results compared to known solid phase systems or other chromatographic separation techniques.
- Target nucleic acids isolated using the mixed-bed solid phase or methods of the present invention are sufficiently free of contaminants to be suitable for use in additional processing, analysis, or even administration to mammals.
- Applications of the present mixed-bed solid phase to isolate nucleic acids from a variety of different media will become apparent from the detailed description of the invention below. Those skilled in the art of this invention will appreciate that the detailed description of the invention is meant to be exemplary only and should not be viewed as limiting the scope of the invention.
- Figure 1 is a theoretical plot of the binding activity of two different anion- exchange solid phases, one (triangles) having a pKa which is significantly lower than the pKa of the second (circles).
- Figure 2 is a copy of a photograph of plasmid DNA fractionated on an agarose gel and stained with ethidium bromide, with arrows showing the points at which the bands of plasmid DNA were excised from the gel prior to isolation of the plasmid DNA therefrom with mixed-bed solid phase particles, as described in Example 11.
- Figure 3 is a copy of a photograph of genomic DNA and total RNA isolated from mouse blood using a mixed-bed solid phase, as described in Examples 14, 17, and 18, fractionated on an agarose gel, and stained with ethidium bromide.
- Figure 4 is a copy of a photograph of total RNA isolated from mouse liver, using a mixed-bed solid phase or using an SV Total RNA Isolation System ® (Promega Corp.), fractionated on an agarose gel with several samples of a lOObp ladder, and stained with ethidium bromide.
- FIG. 5 is a copy of a photograph of DNA amplified with the polyrnerase chain reaction (PCR) and isolated using a mixed-bed solid phase under various wash conditions, and stained with ethidium bromide.
- solid phase is used herein m a standard chromatographic sense, to refer to an insoluble, usually rigid, matrix or stationary phase which interacts with a solute, in this case a target nucleic acid, a solute mixture
- solid phase as used herein, specifically includes stationary phases in liquid chromatography (LC), high pressure liquid chromatography (HPLC), particulate mat ⁇ ces embedded into or bound to filters, and magnetic or non-magnetic porous or non-porous matrix particles which interact w ith solutes when added directly to a solute mixture
- first solid phase and second solid phase refer to separate and distinct solid phase media (e g separate resins, matrix, particle, or filter media) each of which has a different affinity for the target nucleic acid solute m the solute mixture
- mixed-bed solid phase refers to at least two different solid phases in a single container or column (e g , a first solid phase and a second solid phase), wherein each solid phase m the mixed-bed has a different affinity for the solute
- the mixed-bed solid phase can be in any one of a number of different forms or mixtures of forms, including a mixture of at least two different types of chromatography particles (such as a mixture of reversed-phase and ion exchange particles, or a mixture of ion exchange particles with different affinities for a particular target nucleic acid), a mixture of at least two different types of silica magnetic particles (e g , a mixture of silica magnetic particles wherem the surface of one species of particle in the mixture is either silica gel or glass with no functional group attached thereto or silica gel or glass with a siliceous oxide coating, while another species of particle in the mixture has an ion exchange group covalently attached thereto), or a combination of at least
- silica gel refers to chromatography grade silica gel, a substance which is commercially available from a number of different sources Silica gel is most commonly prepared by acidifying a solution containing silicate, e g sodium silicate, to a pH of less than 10 or 1 1 and then allowing the acidified solution to gel See, e g silica preparation discussion in Kurt-Othmer Encyclopedia of Chemical Technology, Vol 21, Mary Howe-Grant, ed , John Wiley & Sons, pub 1997 , pp 1020-1023
- glass particles as used herein means particles of crystalline silicas
- silica magnetic particles refers to silica matnces which are further compnsed of materials which have no magnetic field but which form a magnetic dipole when exposed to a magnetic field, l e , matenals capable of being magnetized in the presence of a magnetic field but which are not themselves magnetic in the absence of such a field
- magnetic as used in this context includes matenals which are paramagnetic or superparamagnetic matenals
- magnetic as used herein, also encompasses temporanly magnetic materials, such as ferromagnetic or fernmagnetic materials
- the silica magnetic particles used in this invention preferably compnse a superparamagnetic core coated with siliceous oxide, havmg a hydrous siliceous oxide adsorptive surface (l e a surface characte ⁇ zed by the presence of silanol groups)
- chaotropic agent as used herein refers to salts of particular
- the first solid phase and second solid phase components of the mixed-bed solid phase of the present invention each have a capacity to bind to and release the target nucleic acid under different solution conditions.
- the first solid phase has the capacity to bind to the target nucleic acid in the presence of a first solution and to release the target nucleic acid in the presence of a second solution
- the second solid phase has the capacity to bind the target nucleic acid in the presence of the second solution and to release the target nucleic acid in the presence of the first solution.
- the target nucleic acid is released from the first solid phase and binds to the second solid phase.
- the mixed-bed solid phase is then separated from the second solution and combined with an elution buffer, wherein the target nucleic acid is released into the elution buffer.
- the mixed-bed solid phase is preferably combined with the first solution and separated therefrom, and/or combined with the second solution and separated therefrom at least one additional time before being combined with the elution buffer.
- the first solid phase and the second solid phase can be made of any common support material, including soft gel supports such as agarose, polyacrylamide, or cellulose, or hard support material such as polystyrene, latex, methacrylate, or silica.
- soft gel supports such as agarose, polyacrylamide, or cellulose
- hard support material such as polystyrene, latex, methacrylate, or silica.
- the solid phase support material is silica, it is preferably in the form of silica gel, siliceous oxide, solid silica such as glass or diatomaceous earth, or a mixture of two or more of the above.
- At least one of the solid phases in the mixed-bed solid phase preferably comprises a silica gel particle.
- Silica gel particles are stable at much higher pressures than solid phases made from soft gel support material, making the silica gel solid phases suitable for HPLC, as well as for LC and batch separation applications.
- Silica materials such as silica gel particles, can bind target nucleic acids in the presence of chaotropic agents. Silica materials can also bind at least one contaminant, such as endotoxins. in the absence of such agents.
- the mixed-bed solid phase mix used in the present invention is preferably in a form which can be separated from a solute mixture comprising the target nucleic acid and at least one contaminant after the solute mixture is combined therewith, by application of an external force.
- an external force suitable for use in separating the mixed-bed solid phase mix from the solute mix depends upon the form in which the mixed-bed solid phase mix is presented to the solute mix, and upon the physical properties of the mixed-bed solid phase itself.
- gravity can be used to separate the mixed-bed solid phase from the solute mix when the mixed-bed solid phase is a mixed-bed resin loaded on an LC column, when the mixed-bed solid phase is a mixed-bed resin or mixture of controlled pore particles (e.g. silica based particles) which are added batch-wise to a solute mixture and then separated therefrom by decantation or filtration, or when the mixed-bed solid phase is embedded into or attached to a filter through which the solute mixture passes.
- the external force is high pressure liquid when the mixed-bed solid phase forms the stationary phase of a high pressure liquid chromatography column (HPLC).
- Other forms of external force suitable for use in the method of this invention include vacuum filtration (e.g.
- mixed-bed solid phase particles such as a mix of other silica- based particles, or embedded into or attached to a filter
- centrifugation e.g. when the mixed-bed solid phase is particulate
- magnetic e.g. when the mixed-bed solid phase comprises magnetic or paramagnetic particles
- Silica materials can be configured for use in the mixed- bed solid phase of the present invention wherein any one or more of the removal means cited above is used.
- Silica based solid phases particularly preferred for use as the first or second solid phases in the mixed-bed solid phase of the present invention include solid phases described in PCT Publication Number WO 95/06652, U.S. Patent No. 6,658,548, PCT Publication Number WO98/31840 and solid phases sold by Promega Corporation for use in plasmid DNA isolation, i.e. Wizard ® Minipreps DNA Purification Resin, all of which are incorporated herein by reference.
- the first or second solid phase is a silica gel particle which is magnetic
- it is preferably a silica magnetic particle, more preferably a siliceous oxide coated (SOCM) silica magnetic particle as disclosed in PCT Publication Number PCT/US98/01 149.
- SOCM siliceous oxide coated
- a silica magnetic particle can be separated from a solution using any of the external means described above for use with other silica matrices. But, the external means used to separate a silica magnetic particle from a solution is preferably magnetic force.
- the first solid phase and second solid phase are preferably both silica magnetic particles.
- the size of the particle is preferably selected as follows. Smaller silica magnetic particles provide more surface area (on a per weight unit basis) for adsorption, but smaller particles are limited in the amount of magnetic material which can be incorporated into such particles compared to larger particles.
- the median particle size of the silica magnetic particles used in a particularly preferred embodiment of the present invention is about 1 to 15 ⁇ m, more preferably about 3 to 10 ⁇ m, and most preferably about 4 to 7 ⁇ m.
- the particle size distribution may also be varied. However, a relatively narrow monodal particle size distribution is preferred. The monodal particle size distribution is preferably such that about 80% by weight of the particles are within a 10 ⁇ m range about the median particle size, more preferably within an 8 ⁇ m range, and most preferably within a 6 ⁇ m range.
- the first and second solid phases of the mixed-bed solid phase of the present invention can be solid or semi-solid, porous, or non-porous. Selection of such properties of each of the solid phases used in the mixed-bed solid phase of the present invention is largely determined by the nature of the target nucleic acid, and by the nature of the material from which it is to be isolated. When pores are present in any of the solid phases in the mixed bed solid phase, at least some of the pores are preferably of a size sufficiently large to admit the target nucleic acid material into the interior of the solid phase particle.
- the silica magnetic particles may contain substances, such as transition metals or volatile organics, which could adversely affect the utility of target nucleic acids substantially contaminated with such substances. Such contaminants can affect downstream processing, analysis, and/or use of target nucleic acids contaminated therewith. For example, such contaminants can nick or degrade the target nucleic acids, or inhibit the activity of enzymes added to the target nucleic acids. Any such substances present in the silica magnetic particles used in the present invention are preferably present in a form which does not readily leach out of the particle and into the isolated biological target material produced according to the methods of the present invention. Iron is one such undesirable contaminant, particularly when the biological target material is a target nucleic acid.
- Iron in the form of magnetite, is present at the core of a particularly preferred form of the silica magnetic particles of the present invention.
- Iron has a broad absorption peak between 260 and 270 nanometers (nm).
- Target nucleic acids have a peak absorption at about 260 nm, so iron contamination in a target nucleic acid sample can adversely affect the accuracy of the results of quantitative spectrophotometric analysis of such samples.
- Any iron containing silica magnetic particles used to isolate target nucleic acids using the present invention preferably do not produce isolated target nucleic acid material sufficiently contaminated with iron for the iron to interfere with spectrophotometric analysis of the material at or around 260 nm.
- the most preferred silica magnetic particles used in the methods and materials of the present invention leach no more than 50 ppm, more preferably no more than 10 ppm, and most preferably no more than 5 ppm of transition metals when assayed as follows. Specifically, 0.33 g of the particles (oven dried @ 110°C) into 20 ml of IN HC1 aqueous solution (using de-ionized water). The resulting mixture is then agitated only to disperse the particles. After about 15 minutes total contact time, a portion of the liquid from the mixture is then analyzed for metals content. Any conventional elemental analysis technique may be employed to quantify the amount of transition metal in the resulting liquid, but inductively coupled plasma spectroscopy (ICP) is preferred.
- ICP inductively coupled plasma spectroscopy
- At least two commercial silica magnetic particles are particularly preferred for use as the first or second silica matrices in the present invention, BioMag ® Magnetic Particles from PerSeptive Biosystems, and MagneSilTM particles available from Promega Corporation. Any source of magnetic force sufficiently strong to separate the silica magnetic particles from a solution would be suitable for use in the present invention.
- the magnetic force is preferably provided in the form of a magnetic separation stand, such as one of the MagneSphere ® Technology Magnetic Separation Stands (Cat. No.'s Z5331 to 3, or Z5341 to 3) from Promega Corporation.
- Target nucleic acids are inherently negatively charged at any pH above pH 2, and can, therefore, reversibly bind to ion-exchangers which are positively charged, at any pH above pH 2.
- some ion-exchangers have an overall positive charge at one pH, where it can act as an anion-exchanger, and an overall neutral or negative charge at another pH.
- Such ion-exchangers are only capable of exchanging ions with a target nucleic acid at a pH and other conditions where the ion-exchanger acts as an anion-exchanger. Capacity for exchange with a target nucleic acid varies widely from one ion-exchanger to another.
- At least one of the solid phases in the mixed-bed solid phase preferably has an ion-exchange residue capable of exchanging with the target nucleic acid covalently attached to the surface of the support material, either directly, or through an intermediary.
- surface refers to the portion of the support material of a solid phase which comes into direct contact with a solution when the solid phase is combined therewith.
- Suitable anion-exchange solid phases for use in the mixed-bed solid phases of the present invention are commercially available.
- the ion-exchange solid phase is preferably a solid support, such as Sepharose (Pharmacia), polystyrene, or a silica based material, with an ion-exchange group covalently attached thereto.
- the ion-exchange group comprises at least one ion- exchange residue, which is capable of acting as an anion-exchanger, wherein the ion- exchange residue is covalently attached to the solid support directly, or through a hydrocarbon linker.
- a hydrocarbon linker it preferably includes at least one residue which can act as a cation exchanger at a pH which is not within the range of pH at which the ion-exchange residue is positively charged.
- mixed-mode solid phase An ion-exchange solid phase with such a linker is referred to herein as a "mixed-mode" solid phase. See U.S. Patent Application Number 09/312,172, filed concurrently for further information about particularly preferred mixed-mode solid phases suitable for use in nucleic acid isolation, incorporated by reference herein.
- the preferred properties of the ion-exchange residue of the ion exchange group are the same.
- the ion-exchange residue preferably has the capacity to exchange readily with the target nucleic acid of interest under solution conditions wherein the target nucleic acid is not chemically degraded (e.g. It is known -21- that RNA degrades in the presence of strongly alkaline solutions, i.e. solutions with pH of 10 or greater, while DNA is stable in such solutions.
- DNA degrades in the presence of concentrated chaotropic agent solutions, such as solutions containing at least 2M guanidine thiocyanate while RNA is stable at guanidine thiocyanate concentrations between 2 and 5M). See, e.g., U.S. Pat. No. 5,346,994.
- the ion exchange group attached to the ion exchange solid phase is most preferably selected from the group consisting of dimethyl-amine, histamine, ethanolamine, histidine, pyridylalanine, and pyridylcysteine.
- the last two preferred ion exchange groups listed above are mixed-mode ion-exchange groups, shown below in a configuration wherein each is covalently attached to a different solid phase.
- the wavy line in the figures below represents the solid phase, such as a silica magnetic particle, to which each of the ion exchange groups is attached:
- the capacity of the first or second solid phase to bind to or exchange with a target nucleic acid under any given solution conditions is a function of functional groups at the surface of the solid phase, whether on the outer surface or lining the exterior surface of pores extending therefrom into each particle of solid phase.
- the target nucleic acid reversibly binds to the anion-exchange functional groups on the surface of the solid phase, under solution conditions (particularly, pH and salt) in which the anion-exchange group is sufficiently charged to exchange ions with the target nucleic acid.
- Anion-exchange solid phases suitable for use in the mixed-bed solid phases of the present invention are commercially available, particularly in the form of nonmagnetic solid phases. See, e.g.
- DEA-SepharoseTM, Q-SepharoseTM, and DEAE- SephadexTM from Pharmacia (Piscataway, New Jersey), Dowex* I from The Do Chemical Company (Midland, Michigan), Amberlite R from Rohm & Haas (Philadelphia, Pennsylvania), Duolite” from Duolite International, In. (Cleveland, Ohio), Dialon Tl, and Dialon TIL
- Anion exchange solid phases suitable for use in the present invention can also be synthesized by covalently attaching any suitable anion- exchange residue to one of the suitable support material described above, using conventional synthetic organic chemistry.
- a suitable anion-exchange solid phase can be produced by covalently attaching a dimethyl-amine residue to a silica based material, such as a silica gel particle or magnetic silica particle, by reacting the silica based material with 3-(diethylamino) propyl trimethoxysilane in the presence of dichloromethane and tributylamine.
- a silica based material such as a silica gel particle or magnetic silica particle
- 3-(diethylamino) propyl trimethoxysilane in the presence of dichloromethane and tributylamine.
- Other anion-exchange residues such as histidine, can be similarly attached to silica based materials to produce suitable anion-exchange solid phases.
- the first solid phase and second solid phase of the mixed-bed solid phase of this invention are selected for their capacity to bind and release a target nucleic acid of interest under different solution conditions, such that the first solid phase binds the target nucleic acid in the presence of a first solution and releases it in the presence of a second solution, while the second solid phase binds the target nucleic acid in the presence of the second solution and releases the target nucleic acid in the presence of the first solution.
- the composition of the first and second solution depends upon the nature of the functional groups at the surface of the first and second solid phases, respectively.
- the first solution when the functional group of the first solid phase is an anion-exchanger, then the first solution contains a sufficiently high salt concentration to provide the ions needed for an ion exchange reaction but not a sufficiently high salt concentration to interfere with the exchange of ions between the anion-exchange groups of the solid phase and the target nucleic acid.
- the pH of the first solution must also be at or below the pKa for the anion-exchange group of a first anion exchange solid phase to ensure the anion-exchange group has a sufficiently positive charge to exchange with the target nucleic acid.
- the pKa of the anion-exchange group of the second solid phase preferably differs from that of the first solid phase by at least 0.5 pKa units, more preferably by at least 1 pKa unit, and most preferably by at least 2 pKa units.
- the first anion-exchange solid phase and the second anion- exchange solid phase can also differ further from one another in capacity to bind the target nucleic acid of interest, due to differences in charge and/or anion-exchange group density at the surface of each such solid phase.
- Figure 1 illustrates a theoretical solid phase mix of a first anion-exchange solid phase and a second anion-exchange solid phase of the present invention, and the selection of first solution, second solution, and elution solution for use in the isolation of a target nucleic acid in accordance with the method of the present invention.
- Figure 1 shows the relative capacities of two different solid phases, A and B, to bind and release a target nucleic acid (RNA or DNA) under various salt and pH conditions.
- Solid phase A has a pKa of 7.0
- solid phase B has a pKa of 8.5.
- Solid phase A also differs from solid phase B in its charge density at different pH's.
- Solid phase A has a higher positive charge density than B in the presence of a solution pH of less than 6.0 and a lower positive charge density than B in the presence of a solution pH of greater than 6.0.
- Solid phase A binds to the target nucleic acid at solution pH and salt concentrations which fall below the A line (dashed) in Figure 1 , and releases target nucleic acid bound thereto at pH and salt concentrations above that same line.
- the B line (dotted) in Figure 1 similarly shows the pH and salt concentrations at which solid phase B binds to (below the line) or releases (above the line) the target nucleic acid.
- Such binding calibration curves can be constructed readily, using standard binding capacity studies.
- Solid phase calibration curves can be used to select the optimal conditions for the first solution, second solution, and elution solutions used in the method of isolating target nucleic acids of the present invention.
- a circle, labeled "solution #1 " in Figure 1 shows solution conditions at which solid phase A will bind to the target nucleic acid, while solid phase B will release any target nucleic acid bound thereto.
- the pH of solution #1 is selected to be as close as possible to a neutral pH while optimizing the difference in binding and releasing capacity of solid phases A and B.
- the circle labeled solution #2 is similarly selected for binding to solid phase B and release from solid phase A in a pH range as close as possible to neutral pH.
- the elution solution composition can be selected from any salt concentration and pH mixture above that of both lines A and B in Figure 1. But, the pH is preferably at about 7 and the salt concentration is preferably as low as possible.
- the first solid phase or the second solid phase is not an anion- exchange solid phase, it is preferably a solid phase material with functional groups on the surface capable of binding directly to the target nucleic acid of interest through interactions other than through ion-exchange such as hydrophobic interaction, reverse- phase interaction, nucleic acid hybridization, or Hoogsteen base pairing.
- the first or second solid phase of the mixed-bed solid phase is a silica based solid phase material, more preferably a silica material having a siliceous oxide coating.
- the silica based solid phase is a silica material with a siliceous oxide coating
- the solid phase is characterized by having silanol groups at the surface of the silica material.
- silica/IE mixed-bed solid phase is used to isolate a target nucleic acid using the method of the present invention, wherein the mixed-bed solid phase is combined with a first solution followed by a second solution, as described above.
- One solution promotes binding with the silica solid phase, while the other promotes binding with the ion exchange solid phase.
- Either solution can be used as the first solution, provided the other solution is the second solution.
- Either the first solution or the second solution preferably contains at least 100 mM, more preferably at least 250 mM, and even more preferably at least 500 mM concentration of a chaotropic agent.
- the chaotropic agent is preferably a guanidine salt, more preferably guanidine thiocyanate.
- Target nucleic acids bind to a silica- based solid phase material readily in the presence of chaotropic agents, but are readily released therefrom in the presence of a solution, which is substantially free of chaotropic agents.
- the term "substantially free”, as used herein means that the concentration of chaotropic agents in a solution in contact with the silica based mixed bed solid phase is sufficiently low that the second solid phase preferentially forms a complex with endotoxins in the solution, and releases any target nucleic acid bound to the other solid phase in the silica/IE mixed-bed solid phase.
- the other (i.e., second or first) solution has the following characteristics.
- the solution is preferably substantially free of chaotropic agents.
- the pH and salt composition of the solution are preferably selected for their capacity to facilitate the exchange of ions between the target nucleic acid and the anion-exchange group of the first solid phase.
- the salt concentration is preferably as low as possible to ensure release of the target nucleic acid from the silica-based solid phase.
- the composition of this solution is preferably a composition, which allows the target RNA, but not DNA to bind to the ion exchange solid phase. More preferably, the composition of this solution promotes binding of the target RNA to at least one solid phase of the mixed-bed solid phase.
- the composition of this solution is preferably a composition which allows the target DNA but not RNA to bind to the ion exchange solid phase. More preferably, the composition of this solution promotes binding of the target DNA to the ion exchange solid phase, but not to the silica-based solid phase component of the silica/IE mixed- bed solid phase. Even more preferably, the composition of the solution promotes binding of endotoxins to the mixed-bed solid phase, more preferably to the silica based solid phase component of a silica/IE mixed-bed solid phase.
- the silica/IE mixed-bed solid phase of the present invention described immediately above is particularly well suited for use in isolating a target nucleic acid from endotoxins in a mixture thereof. Specifically, combination of such a mixed-bed solid phase with a mixture of endotoxins and the target nucleic acid in the presence of a first solution which is substantially free of chaotropic agents, will cause the target nucleic acid to bind to the one solid phase by anion-exchange and the endotoxins to bind to the other solid phase. Endotoxins tend to bind to silica based solid phases, in solutions which are substantially free of chaotropic agents.
- endotoxins can be removed from silica surfaces, such as those found on siliceous oxide coated silica magnetic particles, by washing with water.
- either the first or second solution can be combined with the mixed-bed solid phase in the presence of the target nucleic acid mixture in the first step.
- the solution used first determines which solution is used in the next step. Specifically, if the first solution is combined with the mixed-bed solid phase first, the second solution is combined therewith next, and vice versa. After the initial combining step, the mixed-bed solid phase is separated from the initial solution and combined with the other solution. The combining and separation steps are preferably repeated until the mixed-bed solid phase has been combined with and separated from each of the first and second solutions at least twice. At each change from the first to the second solution, at least 90% of the target nucleic acid remains bound to the mixed-bed solid phase, while at least one contaminants are removed therefrom.
- the method of the present invention will further comprise a step of washing the mixed-bed solid phase between solution addition steps and/or after separation from the final solution and prior to the elution step. Wash steps are particularly preferred, after contact with a first or second solution containing a chaotropic agent (e.g., GTC) prior to contact with a first, second, or elution solution which is substantially free of chaotropic agents.
- a chaotropic agent e.g., GTC
- the composition of any such wash buffer is selected to ensure the target nucleic acid remains bound to the mixed-bed solid phase.
- Water is preferably used to wash the mixed-bed solid phase of a first anion-exchange solid phase and second silica based solid phase illustrated above, to ensure complete removal of chaotropic agent after addition of the second solution thereto.
- the first solution, second solution, and any wash solution are all preferably prepared from or consist of distilled, deionized, or nanopure water.
- nanopure water refers to water purified with an ultrafiltration system which produces water of comparable quality to a Nanopure* Filtration System.
- the distilled, deionized, or nanopure water can be autoclaved or filtered prior to use in the method. However, during such additional processing steps, impurities can be introduced into the water, such as a weak buffer of greater than pH 5.0.
- Such impurities can raise the pH of the water to such an extent that it can cause target nucleic acids, particularly amplified nucleic acids (e.g., PCR amplified DNA), to be released from a mixed-bed resin when placed into contact therewith.
- target nucleic acids particularly amplified nucleic acids (e.g., PCR amplified DNA)
- W ien the target nucleic acid is RNA
- any water placed into direct contact with the mixed-bed solid phase must be substantially RNAse free.
- Elution of the target nucleic acid from the mixed-bed solid phase is carried out in the presence of an elution buffer selected for its capacity to ensure the release of the target nucleic acid from the mixed-bed solid phase.
- the target nucleic acid eluted from the mixed-bed solid phase in the final step of the method is sufficiently pure to be used in applications sensitive to contamination with endotoxins and other at least one contaminants, applications including transfection of tissue culture cells.
- silica magnetic particles used in each of the Examples below were selected from either of two batches of particles. Both batches of silica magnetic particles were found to produce acceptable results when tested as described below.
- One of the two batches of particles used below had the following physical characteristics: surface area of 55 mJg, pore volume of 0.181 ml/g for particles of ⁇ 600 A diameter, pore volume of 0.163 ml/g for particles of >600 A diameter, median particle size of 5.3 ⁇ m, and iron leach of 2.8 ppm when assayed as described herein above using ICP.
- the other batch of silica magnetic particles used below was found to have the following characteristics: surface area of 49 m 2 /g, pore volume of 0.160 ml/g ( ⁇ 600 A diameter), pore volume of 0.163 ml/g (>600 A diameter), median particle size of 5.5 ⁇ m, and iron leach of 2.0 ppm.
- Samples of target nucleic acids isolated according to procedures described in Examples below were analyzed for contamination with non-target nucleic acids, and for size as follows.
- the samples were fractionated on an agarose gel of appropriate density (e.g., a 0.7% agarose gel was used to analyze plasmid DNA, while a 1.5% agarose gel was used to analyze RNA).
- the fractionated nucleic acid was visualized using a fluorescent label or by dying the gel with a DNA sensitive stain, such as ethidium bromide or silver staining.
- the resulting fractionated, visualized nucleic acid was either photographed or visualized using a fluorimager and the resulting image printed out using a laser printer.
- size standards were fractionated on the same gel as the target nucleic acid, and used to determine the approximate size of the target nucleic acid. In every case where a gel assay was done, the photograph or fluorimage of the fractionated nucleic acid was inspected for contamination by non-target nucleic acids.
- images of fractionated samples of plasmid DNA were inspected for RNA, which runs considerably faster than DNA on the same gel, and for chromosomal DNA, which runs considerably slower than plasmid DNA on the same gel. Images of isolated plasmid DNA were also inspected to determine whether most of the plasmid DNA shown in the image is intact, supercoiled, plasmid DNA.
- a limulus amoebocyte lysate (LAL) gel precipitation assay was conducted to determine the number of units of endotoxin in bacteria lysate samples taken before and after the lysate solutions came into contact with one or more of the silica matrices tested in Examples below.
- E-TOXATE ® from SIGMA ® (St. Louis, MO, cat. no. 210- Dl) was used as the amoebocyte lysate standard for this series of LAL assays.
- E- TOXATE ® is described in the 1997 SIGMA ® Catalog (p. 448) as "(Amoebocyte lysate; Horseshoe crab lysate) from Limulus Polyphemus ' ".
- Endotoxin-free water (“ETF water”) was used in all the steps of this assay, including all the dilution steps. Each sample or set of samples was assayed according to the following procedure: 1. Samples were prepared for serial dilution, with a larger initial dilution factor used (e.g., 1 : 10000 or higher) for samples which had not been in contact with any endotoxin removal agent, such as silica gel particles, and with smaller initial dilutions of 1 :500 to 1 :1000 for samples which had come into contact with such agents. Endotoxin-free (“ETF”) water was used for all dilutions described herein. 2.
- ETF Endotoxin-free
- lOO ⁇ l of the Endotoxin Standard from the bottle diluted as described above was transferred to tube 1 , mixed, and then serially diluted as follows: lOO ⁇ l from tube 1 was added to tube 2 and mixed, for 40 Endotoxin Units ("EU") per milliliter (ml.), lOO ⁇ l from tube 2 was added to tube 3 and mixed, for 4 EU/ml, 150 ⁇ l from tube 3 was added to tube 4 and mixed, for 0.5 EU/ml, 500 ⁇ l from tube 4 was added to tube 5 and mixed, for 0.25 EU/ml,
- EU Endotoxin Units
- 500 ⁇ l from tube 5 was added to tube 6 and mixed, for 0.125 EU/ml, 500 ⁇ l from tube 6 was added to tube 7 and mixed, for 0.06 EU/ml, 500 ⁇ l from tube 7 was added to tube 8 and mixed, for 0.03 EU/ml, 500 ⁇ l from tube 8 was added to tube 9 and mixed, for 0.015 EU/ml. 4.
- Endotoxin Standards diluted as described above and a blank standard were then transferred to a microtiter plate as follows: 25 ⁇ l ETF water (blank) in column 1, 25 ⁇ l from standard tube 4 in column 2, 25 ⁇ l from standard tube 5 in column 3, 25 ⁇ l from standard tube 6 in column 4, 25 ⁇ l from standard tube 7 in column 5, 25 ⁇ l from standard tube 8 in column 6, and 25 ⁇ l from standard tube 9 in column 7.
- E-TOXATE ® i.e. LAL in lyophilized form
- ETF water was added to each bottle of E-TOXATE* to a final concentration contains, and an amount of ETF water was added to each bottle to bring about 5 ml of ETF water was added to each bottle.
- E-TOXATE u When multiple bottles of E-TOXATE u were opened for a single set of assays, the bottle contents were resuspended in ETF water, as described immediately above, and combined prior to use. 25 ⁇ l of E-TOXATE " was added to each well of each microtiter plate containing a sample, standard, or blank.
- DNA isolated according to procedures described below was also used to transfect HeLa cells, a human ovarian cancer cell line.
- the cells were cultured in
- DMEM Dulbecco's Modified Eagles Medium
- 10% fetal bovine serum 10%
- the cells were plated in 24 well dishes in appropriate media and the following procedure was followed.
- the cells were placed in 24 well dishes, about 50,000 cells per well, approximately 24 hours before initiating transfection.
- a mixture of each of the four Samples of DNA was prepared as follows. Enough mixture of each sample of DNA was prepared to transfect six wells of cell culture, as follows. 6 ⁇ l (about 6 ⁇ g) of DNA, 23.8 ⁇ l of calcium chloride, and 160 ⁇ l of sterile water were combined in a sterile polystyrene tube. The DNA CaCL mixture prepared above was added, dropwise, to 190.2 ⁇ l of Hank's Buffered Saline (HBS), while gently vortexing the HBS.
- HBS Hank's Buffered Saline
- the HBS/DNA/CaC mixture was incubated for 30 minutes at room temperature, before adding 54.6 ⁇ l of the mixture to each well of cells. The mixture was added directly to the media containing serum.
- the cells were harvested by removing the growth medium and adding lOO ⁇ l of cell culture lysis reagent per well.
- luciferase gene of pGL3 plasmid DNA
- a standard luciferase assay the Luciferase Assay System commercially available from Promega Co ⁇ oration, was used to detect and quantify luciferase expression in the cells.
- a diethylamino (DEA) anion exchange residue was covalently attached to MagneSilTM Particles through a propyl dimethoxy silane ligand according to the following synthesis procedure:
- MagneSilTM particles were activated by drying at 120°C in a vacuum oven overnight.
- Cell Resuspension Solution 50mM Tris-HCI, pH 7.5 lOmM EDTA 1 OO ⁇ g/ml
- DNase-free ribonuclease A RNase A
- the cells from 10 ml of bacteria culture were harvested by centrifuging the culture for 1-2 minutes at top speed in a microcentrifuge.
- the harvested cells were resuspended in 250 ⁇ l of Cell Resuspension Solution, and transferred to a microcentrifuge tube.
- the resulting solution of resuspended cells was cloudy.
- Example 6 by binding to and eluting plasmid DNA contained therein from either silica magnetic particles, DEA-silica magnetic particles prepared as described in Example 4, or a mixture of the two types of particles, as follows.
- the mixture of silica magnetic particles and DEA-silica magnetic particles used in this Example are referred to herein as "Silica DEA Mixed Bed” particles.
- the single particle binding and elution procedures were included as controls.
- Control 1 Plasmid DNA Isolated from Lysate with GTC, Using Silica
- the first control sample of plasmid DNA was isolated from a lysate solution using the silica magnetic particles alone, as follows.
- the lysate was prepared according to Example 4, using #5 Neutralization Solution (i.e. Neutralization Solution with 2.26M GTC).
- 150 ⁇ l MagneSil " particles suspended in water, for a final concentration of 100 mg of particles per ml, were added to 250 ⁇ l of the lysate and then removed from the lysate using magnetic force. The particles were then suspended in and removed from 1.0 ml of 0.85M GTC by magnetic force twice. After the second removal step, the particles were suspended and removed from 1.0 ml of
- plasmid DNA was isolated from DEA-magnetic silica particles synthesized as described in Example 4, above, according to the following procedure.
- the lysate was prepared according to Example 1 , using Wizard Neutralization Solution (i.e. Neutralization Solution with no GTC).
- 150 ⁇ l of DEA- silica magnetic particles (suspended in water for a 100 mg/ml concentration) were added to 250 ⁇ l of the lysate and then removed from the lysate using magnetic force.
- the particles were then resuspended one time in 1.0 ml of Wash Solution B, followed by three resuspensions in 1.0 ml water, wherein magnetic force was used to remove the particles from the wash solution after each resuspension step.
- Plasmid DNA Isolated from Lysate with GTC Using Silica/IE-DEA Mixed-Bed Solid Phase Plasmid DNA was isolated from lysate prepared as described in Example 6, using Wizard ® Neutralization Solution (no GTC) using a mixed-bed solid phase of 15 mg of the silica magnetic particles and 30 mg of the DEA-silica magnetic particles (water was removed from the mixed-bed solid phase particles prior to lysate addition), as follows:
- the lysate was combined with 15 mg MagneSilTM and 30 mg DEA- magnetic silica particles, mixed and separated therefrom by magnetic force. The lysate was discarded.
- the particles were resuspended in 950 ⁇ l of Wash Solution B, mixed, and separated therefrom by magnetic force. This step was repeated twice, discarding the wash solution after each separation step. 3.
- the particles were resuspended in 950 ⁇ l of 2M GTC, and separated therefrom by magnetic force. This step was repeated once, and the GTC solution discarded after each separation step. 4.
- the particles were resuspended in 950 ⁇ l of 0.85M GTC, and separated therefrom by magnetic force. This step was repeated once, and the GTC solution discarded after each separation step.
- the particles were resuspended in 950 ⁇ l of water, and separated therefrom by magnetic force. This step was repeated once, and the water discarded after each separation step.
- Silica/IE-DEA Mixed-Bed Solid Phase Plasmid DNA was also isolated from lysate prepared as described in Example 6, using #5 Neutralization solution, using the silica IE-DEA Mixed-Bed solid phase, as follows: 1. The lysate was combined with 15 mg silica magnetic particles and 30 mg DEA-silica magnetic particles, mixed and separated therefrom by magnetic force. The lysate was discarded.
- the particles were resuspended in 950 ⁇ l of water, mixed, and separated therefrom by magnetic force. This step was repeated once, discarding the water wash solution after each separation step.
- Plasmid DNA was precipitated out of each control and test sample of eluent produced as described above, as follows. 800 ⁇ l of 95% ethanol was combined with each 300 ⁇ l sample of eluent, and stored at -20°C for 60 hours in a microcentrifuge tube. The resulting DNA precipitate was then spun out of solution by centrifugation for 10 minutes at 12,000g in a microcentrifuge. The ethanol supernatant was discarded, and the pellet washed with 500 ⁇ l of 70% ethanol. The second ethanol wash solution was similarly removed by centrifugation, and the pellet dried. The resulting pellet of DNA was then resuspended in 80 ⁇ l ETF water.
- EXAMPLE 9 - RESULTS OF ASSAY OF ENDOTOXINS AND TRANSFECTION EFFICIENCY OF PLASMID DNA ISOLATED FROM LYSATE IN EXAMPLE 7
- Example 8 The same control and test samples assayed in Example 8 were also assayed for endotoxin contamination according to the procedure described in Example 3, above, and for transfection efficiency according to the procedure described in Example 4, above. Both sets of assay results are shown in Table 2, below:
- a second silica/ion exchange mixed bed solid phase was produced, as follows, for use in the additional nucleic acid isolation examples, below (l e , Examples 11 to 12)
- the second silica/ion exchange mixed bed was produced by combining equal amounts of the same type of silica magnetic particles used abov e with ion exchange silica magnetic particles, wherem the ion exchange particles are silica magnetic particles with histidine residues covalently attached thereto (hereinafter, "IE-His particles")
- IE-His particles silica magnetic particles with histidine residues covalently attached thereto
- 50 ⁇ l of a 100 mg/ml solution of the silica magnetic particles was combined with 50 ⁇ l of a 100 mg/ml solution of the IE-His particles
- the resulting mixture is referred to herein as the "Silica/His Mixed Bed" solid phase
- the IE-His particles used to make the Silica/His Mixed Bed solid phase were produced using a silica activation and ligand attachment procedure substantially similar to the procedure used to produce the IE-DEA silica magnetic particles in Example 5, above. Histidine was selected as a ligand because of its known properties as an excellent anion exchanger in the neutral to basic pH range.
- EXAMPLE 1 1 - ISOLATION OF PLASMID DNA FROM AGAROSE, USING SILICA/IE-HIS MIXED BED SOLID PHASE
- plasmid DNA was also extracted from bands of the same DNA cut from the same agarose gel, using silica magnetic particles, as described below.
- Plasmid DNA was fractionated on an agarose gel and excised therefrom, as follows. 20 ⁇ g of pGL3 plasmid DNA was ahquoted into each of five different wells of a 1%) agarose gel, and electrophoresed for a sufficient amount of time to clearly separate plasmid DNA from chromosomal or RNA contaminants in each lane. The gel was then stained with ethidium bromide, and the bands visualized under ultraviolet light. The bands were individually excised from the gel (band weight ranged from 0.51 g. to 0.56 g per slice). Figure 2 shows the agarose gel and excision points from which the plasmid DNA bands were excised from the gel. Once excised from the gel, each band was dissolved in 550 ⁇ l of a GTC Buffer
- control sample tube of dissolved gel slices mixture and silica magnetic particles prepared as described above, was processed as follows:
- control sample was incubated for 20 minutes at room temperature, resuspending the silica magnetic particles in the mixture twice midway through the incubation period.
- the silica magnetic particles were then removed from all liquid in the incubation mixture, by magnetic force. 3. The silica magnetic particles were then washed three times with 500 ⁇ l of 70% ethanol added to the particles in each wash step. Magnetic force was used to remove the wash solution from the silica magnetic particles, after each addition of ethanol wash solution. 4. The silica magnetic particles were allowed to air dry for at least 15 minutes after the final wash and magnetic separation step. 5. DNA was eluted from the silica magnetic particles with 100 ⁇ l of
- Bed Solid Phase particles prepared as described above, was processed as follows: 1. The tube of control sample was incubated for 20 minutes at room temperature, resuspending the mixed-bed particles in the mixture twice midway through the incubation period. 2. The silica magnetic particles were then removed from all liquid in the incubation mixture, by magnetic force.
- Tris Buffer pH 8.7
- control and test sample eluents produced as described above were then tested for yield and purity, using the spectrophotometric analysis procedure set forth in Example 2, above. Both the yield and purity of plasmid DNA were higher in the test sample, the eluent from the mixed-bed solid phase. Specifically, the A 26 o for the control sample (i.e., the eluent from the silica magnetic particles, alone) was measured at 0.0104, while the A 260 for the test sample (i.e., the eluent from the Silica/IE-His Mixed Bed) was measured at 0.0166. Thus, the A 260 results indicated that a significantly higher yield of plasmid DNA was recovered from the agarose samples compared to the control.
- the control sample A 26 o/A 280 was measured at 1.54, while the test sample A 2 o/A 28 o was found to be 1.89.
- the absorbance ratio results indicated, furthermore, that the plasmid DNA isolated from the agarose using the mixed-bed solid phase was of a higher purity than plasmid DNA isolated from the agarose using silica magnetic particles, alone.
- Adenometous polyposis coli (APC) gene was fractionated on an agarose gel, and a band corresponding in size to the 1.8 Kb fragment was excized therefrom. The excised band weighed 725 mg. 2. 725 ⁇ l of a GTC Buffer (4.0M GTC, 1.7M Na + , and 2.1M Acetate, pH
- FIG. 5 is a photograph of the gel, after it was stained with ethidium bromide, and illuminated under ultraviolet light. The lanes of the gel shown in Figure 5 were loaded as follows:
- Figure 5 shows that the samples in lanes 1-3 and 5 all contained the expected band at about 1.8 Kb. However, the band in lane 5 was considerably less intense than that in lane 2, and no band was visible in lane 4. It appears the nanopure water worked best at washing the particles, without eluting the DNA therefrom in step 5, above.
- Genomic DNA and total RNA were partially isolated from mouse blood from Lampire Biological Laboratories (Pipersville, PA), using reagents from an SV Total RNA Isolation System (Promega, cat. no. Z3100), as follows. The resulting mixture of genomic DNA and total RNA was then further processed to isolate genomic DNA therefrom, using three different substrates and protocols, according to the procedures of Examples 15 to 17, below. Total RNA could also be isolated from the mixture of genomic DNA and total RNA produced as described herein, according to the procedure of theoretical Example 19, below.
- SV RNA Red Blood Cell Lysis Solution 5 mM MgCl 2 10 mM NaCI lO mM Tris-HCI (pH 7.0) SV RNA Lysis Buffer
- RNA and genomic DNA were produced from samples of the mouse blood cells, as follows: 1. 1.0 ml of mouse whole blood cells was aliquotted into each of twelve microfuge tubes.
- the resuspended cell/lysis solution mixture was centrifuged at 4,000 ⁇ m for 2 minutes. The resulting supernatant was removed with a pipette and discarded, leaving behind a white blood cell pellet and a pellet of erythrocyte debris above the white cells. Liquid was removed from the microcentrifuge tube caps during this step and all remaining steps of this procedure.
- Steps 3 and 4 were repeated twice, for a total of three times. For blood volumes greater than 600 ⁇ l, 200 ⁇ l of the erythrocyte debris was removed, leaving several hundred microliters of erythrocyte debris in the tube.
- the cell pellet was vortexed for 5 seconds on a high speed setting, to resuspend the white cells and the erythrocyte debris.
- the empty spin basket was spun again at 12 to 14K for 20 seconds to remove residual wash solution from the basket.
- Magnetic force was used to separate the silica magnetic particles from the liquid portion of the mixture, after the incubation period was over. The liquid was discarded.
- the silica magnetic particles were then washed four times with 1 ml of 70% ethanol.
- the ethanol wash solution was separated from the silica magnetic particles by magnetic force. The wash solution was discarded after each wash step.
- the silica magnetic particles were allowed to dry in the microcentrifuge tube at room temperature until the ethanol had evaporated therefrom.
- Example 14 were transferred to separate microcentrifuge tubes, each of which contained 50 ⁇ l 100 mg/ml of Silica/IE-His Mixed Bed Solid Phase particles. The tubes were incubated at room temperature for 5 minutes, resuspending the particles in the mixture twice about half-way through the incubation period. The following procedure was then followed to isolate genomic DNA from other materials in the mixture:
- Magnetic force was used to separate the mixed-bed solid phase particles from the liquid portion of the mixture, after the incubation period was over. The liquid was discarded.
- the mixed-bed solid phase particles were then washed four times with 1.0 ml each of nanopure water, separating the water from the mixed-bed solid phase particles after each wash step by magnetic force. The wash solution was discarded after each wash step.
- mice genomic DNA of comparably high purity and yield was obtained using each of the procedures described in Examples 15-17 to isolate the DNA from the same mixture of DNA and RNA produced from the same amount (1ml) of mouse blood, according to the lysis and preliminary isolation procedure of Example 14.
- the A 26 rJA 28 o ratio for each of the samples tested fell within the range between 1 JO and 1.90, the expected range for genomic DNA which is relatively free of protein contamination.
- the A 3 o results obtained herein show that all the means for removing guanidine from the solid support used to isolate genomic DNA prior to elution of the DNA therefrom were approximately equally effective.
- two of the isolation methods used to obtain the samples tested herein required time consuming evaporation or extra centrifugation steps prior to DNA elution to ensure removal of guanidine from the solid support used in each such method. See, e.g., evaporation during spin step 3 with empty spin basket in Example 15, and evaporation of wash solution from particles in step 3 of Example 16. Contrastingly, no such evaporation step was used prior to elution of the genomic DNA from the mixed-bed solid phase, in accordance with the isolation procedure described in Example 16, above. Specifically, in that particular example, the aqueous wash solutions combined with and removed from the mixed-bed solid phase prior to the elution step dissolved and removed residual guanidine therefrom.
- a mixture of ethanol and a cleared lysate of mouse liver tissue was prepared according to the tissue lysate preparation procedure set forth in the SV Total RNA Isolation System Technical Manual (Promega, TM #48), as follows:
- Lysis Buffer combining 171 mg of liver tissue to each milliliter of Lysis Buffer. Homogenization was continued until lysis was complete (i.e., until no visible tissue fragments remained in the solution). 2. 175 ⁇ l of the lysate was transferred to each of six 1.5 ml microcentrifuge tubes. 350 ⁇ l of SV RNA Dilution Buffer (blue) (See Example 14) was added to each tube. The contents of each microcentrifuge tube were mixed by inversion. The diluted lysate was then placed in a water bath or heating block at 70°C, and incubated for about 3 minutes. 3.
- Total mouse RNA was then isolated from four samples of the ethanol/lysate mixture prepared from mouse livers, as described in Example 19, above, using two different mixed-bed solid phases.
- One of the two mixed-bed solid phases was a silica/IE-His mixed-bed solid phase of porous silica magnetic particles, prepared as described in Example 10, above.
- the other mixed-bed solid phase used herein was prepared in the same way as the porous silica/IE-His mixed-bed solid phase, except that non-porous silica magnetic particles were used instead of porous particles.
- the same procedure was used to isolate total RNA from each sample using both types of mixed-bed solid phases.
- Magnetic force was used to separate the mixed-bed solid phase particles from the supernatant/ethanol mixture. The liquid separated therefrom was discarded.
- the mixed-bed solid phase particles were washed four times with 1.0 ml each of nanopure water, separating the water from the mixed-bed solid phase particles after each wash step by magnetic force. The wash solution separated therefrom was discarded after each wash step.
- nuclease free water was added to the mixed-bed solid phase particles after the last wash step, and incubated for 5 minutes at room temperature.
- the water/particle mixture was spun in a microcentrifuge at 12 to 14K for ten seconds. The resulting eluent was removed from the resulting pellet of silica magnetic particles, and tested as described in Example 22, below.
- EXAMPLE 21 ISOLATION OF TOTAL RNA FROM ETHANOL/LYSATE OF MOUSE LIVERS, USING SV RNA SPPN BASKET ASSEMBLY Total mouse RNA was then isolated from the remaining two samples of the ethanol/lysate mixture prepared from mouse livers, as described in Example 19, above, using an isolation procedure described in the SV Total RNA Isolation System Technical Manual (TM #48, Promega Co ⁇ .), as follows:
- Wash step 3 was repeated using 250 ⁇ l of SV RNA Wash Solution, and high speed centrifugation for two minutes.
- EXAMPLE 22 COMPARISON OF DNA AND TOTAL RNA ISOLATED FROM MOUSE BLOOD USING SILICA/IE-HIS MIXED BED SOLID PHASE 20 ⁇ l of each sample of genomic DNA and total RNA isolated from mouse blood with silica/IE-HIS mixed bed solid phase as described in Examples 17 and 21, respectfully, were fractionated on an agarose gel, and stained with ethidium bromide. A photograph of the gel is reproduced in Figure 3. The lanes of the gel were loaded as follows: Lanes A, B, and C were loaded with isolated total RNA
- Lanes 1-3 were loaded with DNA isolated using Wash Solution A
- Lanes 4-6 were loaded with DNA isolated using Wash Solution B. From the gel assay results, it appears intact RNA and DNA were isolated from mouse blood, although the amount of RNA isolated was small by comparison to the DNA. It also appears that DNA isolated with either Wash solution used in step 2 was substantially intact, and appeared to be free of contamination with RNA.
- RNA eluted from each of the isolation means used in Examples 19-21 , above was analyzed using gel electrophoresis as follows. lO ⁇ l of each sample was loaded into a separate well of a 1.5% agarose gel, with samples eluted from the same isolation means loaded in pairs separated by a 100 bp DNA ladder (Promega Cat. No. G2101) was loaded into the empty well between each pair of samples. The 1.5% agarose gel was then electrophoresed for a sufficient amount of time to provide clear separation between the rungs of the 100 bp ladder. Finally, the agarose gel was stained with ethidium bromide, and photographed under ultraviolet light.
- Figure 4 is a copy of the photograph of the 1.5% agarose gel of the samples and ladders loaded and fractionated as described above. The following samples were loaded onto each lane of the gel shown in Figure 4:
- Lane 1 Promega 100 bp DNA ladder
- Lanes 2 & 3 Eluent from porous silica/IE-His mixed bed solid phase
- Lanes 5 & 6 Eluent from SV RNA Spin Basket Lane 7: 100 bp DNA ladder
- Lanes 8 & 9 Eluent from non-porous silica/IE-His mixed bed solid phase
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000618447A JP2002543980A (en) | 1999-05-14 | 2000-05-12 | Mixed bed solid phase and its use in nucleic acid isolation |
AU48415/00A AU774810B2 (en) | 1999-05-14 | 2000-05-12 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
EP00930626A EP1179056B1 (en) | 1999-05-14 | 2000-05-12 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
CA002372521A CA2372521C (en) | 1999-05-14 | 2000-05-12 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
DE60012506T DE60012506T2 (en) | 1999-05-14 | 2000-05-12 | MIXED BED FIXED PHASE AND ITS USE FOR THE ISOLATION OF NUCLEIC ACIDS |
AT00930626T ATE272111T1 (en) | 1999-05-14 | 2000-05-12 | MIXED BED SOLID PHASE AND ITS USE FOR ISOLATION OF NUCLEIC ACIDS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/312,139 | 1999-05-14 | ||
US09/312,139 US6270970B1 (en) | 1999-05-14 | 1999-05-14 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000070041A1 true WO2000070041A1 (en) | 2000-11-23 |
Family
ID=23210049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012954 WO2000070041A1 (en) | 1999-05-14 | 2000-05-12 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
Country Status (8)
Country | Link |
---|---|
US (2) | US6270970B1 (en) |
EP (1) | EP1179056B1 (en) |
JP (1) | JP2002543980A (en) |
AT (1) | ATE272111T1 (en) |
AU (1) | AU774810B2 (en) |
CA (1) | CA2372521C (en) |
DE (1) | DE60012506T2 (en) |
WO (1) | WO2000070041A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6914137B2 (en) | 1997-12-06 | 2005-07-05 | Dna Research Innovations Limited | Isolation of nucleic acids |
WO2008045505A2 (en) | 2006-10-10 | 2008-04-17 | Xenomics, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
US8691969B2 (en) | 1994-12-12 | 2014-04-08 | Life Technologies As | Isolation of nucleic acid |
US8865405B2 (en) | 2001-11-28 | 2014-10-21 | Applied Biosystems Llc | Compositions and methods of selective nucleic acid isolation |
EP2757156A4 (en) * | 2011-09-13 | 2015-08-26 | Sony Corp | Nucleic acid purification method, nucleic acid extraction method, and nucleic acid purification kit |
WO2018215375A1 (en) * | 2017-05-22 | 2018-11-29 | General Electric Company | Improvements in the recovery of nucleic acids from solid supports |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1036082E (en) * | 1997-12-06 | 2002-10-31 | Dna Res Innovations Ltd | ISOLATION OF NUCLEIC ACIDS |
US7078224B1 (en) * | 1999-05-14 | 2006-07-18 | Promega Corporation | Cell concentration and lysate clearance using paramagnetic particles |
AU2862100A (en) * | 1999-01-27 | 2000-08-18 | Folim G. Halaka | Materials and methods for the purification of polyelectrolytes |
DE10013990C2 (en) * | 2000-03-22 | 2003-12-04 | Invitek Biotechnik & Biodesign | Polyfunctional carrier material for complex nucleic acid analysis |
US20050239125A1 (en) * | 2000-09-06 | 2005-10-27 | Hodge Timothy A | Methods for genotype screening |
US20050272085A1 (en) * | 2000-09-06 | 2005-12-08 | Hodge Timothy A | Methods for forensic and congenic screening |
US20050266494A1 (en) * | 2000-09-06 | 2005-12-01 | Hodge Timothy A | System and method for computer network ordering of biological testing |
EP1978110B1 (en) * | 2000-09-06 | 2010-05-26 | Transnetyx, Inc. | Computer-based method and system for screening genomic DNA |
US20030087286A1 (en) * | 2000-09-06 | 2003-05-08 | Hodge Timothy A. | Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles |
US7494817B2 (en) * | 2000-09-06 | 2009-02-24 | Transnet Yx, Inc. | Methods for genotype screening using magnetic particles |
US20030082605A1 (en) * | 2000-09-06 | 2003-05-01 | Hodge Timothy A. | Genomic DNA detection method and system thereof |
US20030207289A1 (en) * | 2001-09-04 | 2003-11-06 | Hodge Timothy A. | Detection of genetic sequences using a bipartite probe |
JP4198461B2 (en) * | 2000-11-13 | 2008-12-17 | プロメガ コーポレイション | Lysate clearance and nucleic acid isolation using silane-treated silica substrates |
EP1349951A4 (en) * | 2001-01-09 | 2005-08-24 | Whitehead Biomedical Inst | Methods and reagents for the isolation of nucleic acids |
US20060014186A1 (en) * | 2001-09-04 | 2006-01-19 | Hodge Timothy A | Methods for genotype screening of a strain disposed on an adsorbent carrier |
US7893228B2 (en) * | 2001-10-12 | 2011-02-22 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify RNA |
US7148343B2 (en) * | 2001-10-12 | 2006-12-12 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
US6833238B2 (en) | 2002-01-04 | 2004-12-21 | Applera Corporation | Petal-array support for use with microplates |
CA2473376A1 (en) | 2002-01-16 | 2003-07-31 | Dynal Biotech Asa | Method for isolating nucleic acids and protein from a single sample |
GB0207975D0 (en) * | 2002-04-05 | 2002-05-15 | Genovision As | Isolating nucleic acid |
GB0209382D0 (en) * | 2002-04-24 | 2002-06-05 | Genovision As | Isolating nucleic acid |
US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
US20040018559A1 (en) * | 2002-07-26 | 2004-01-29 | Applera Corporation | Size-exclusion ion-exchange particles |
US20060160085A1 (en) * | 2002-11-08 | 2006-07-20 | Timo Hillebrand | Novel buffer formulations for isolating purifying and recovering long-chain and short-chain nucleic acids |
EP1592505A2 (en) * | 2003-01-21 | 2005-11-09 | Micronics, Inc. | Method and system for microfluidic manipulation, amplification and analysis of fluids, for example, bacteria assays and antiglobulin testing |
WO2004086055A1 (en) * | 2003-03-24 | 2004-10-07 | Sony Corporation | Microchip, nucleic acid extracting kit, and nucleic acid extracting method |
US20040197780A1 (en) * | 2003-04-02 | 2004-10-07 | Agencourt Bioscience Corporation | Method for isolating nucleic acids |
US20050042660A1 (en) * | 2003-07-31 | 2005-02-24 | Hall Gerald Edward | Devices and methods for isolating RNA |
US20050026153A1 (en) * | 2003-07-31 | 2005-02-03 | Iannotti Claudia A. | Devices and methods for isolating RNA |
CN100543126C (en) * | 2003-08-19 | 2009-09-23 | 富士胶片株式会社 | Extraction element |
US20050106576A1 (en) * | 2003-11-17 | 2005-05-19 | Hashem Akhavan-Tafti | Methods of using cleavable solid phases for isolating nucleic acids |
US20050106577A1 (en) * | 2003-11-17 | 2005-05-19 | Hashem Akhavan-Tafti | Cleavable solid phases for isolating nucleic acids |
US20050181378A1 (en) * | 2004-02-18 | 2005-08-18 | Applera Corporation | Polyelectrolyte-coated size-exclusion ion-exchange particles |
US20060160122A1 (en) * | 2004-02-18 | 2006-07-20 | Applera Corporation | Polyelectrolyte-coated size-exclusion ion-exchange particles |
US20050196856A1 (en) * | 2004-02-18 | 2005-09-08 | Applera Corporation | Polyelectrolyte-coated size-exclusion ion-exchange particles |
SE0400490D0 (en) * | 2004-02-26 | 2004-02-26 | Amersham Biosciences Ab | Plasmid purification |
JP4476050B2 (en) * | 2004-06-30 | 2010-06-09 | 株式会社ニデック | Perimeter |
WO2006015326A2 (en) * | 2004-07-30 | 2006-02-09 | Agencourt Bioscience Corporation | Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers |
US20060099605A1 (en) * | 2004-11-11 | 2006-05-11 | Hall Gerald E Jr | Devices and methods for isolating RNA |
CA2586532C (en) | 2004-11-05 | 2014-03-25 | Qiagen North American Holdings, Inc. | Compositions and methods for purifying nucleic acids from stabilization reagents |
EP1693108A1 (en) * | 2004-12-04 | 2006-08-23 | MERCK PATENT GmbH | Mixed-modal anion-exchange type separation material |
US20060223073A1 (en) * | 2005-03-31 | 2006-10-05 | Boyes Barry E | Methods of using a DNase I-like enzyme |
US20060223072A1 (en) * | 2005-03-31 | 2006-10-05 | Boyes Barry E | Methods of using a DNase I-like enzyme |
US20060234251A1 (en) * | 2005-04-19 | 2006-10-19 | Lumigen, Inc. | Methods of enhancing isolation of RNA from biological samples |
US20060269929A1 (en) * | 2005-05-26 | 2006-11-30 | Hall Gerald E Jr | Methods and kits for DNA purification on polymeric membranes at low ionic strength |
US20060270843A1 (en) * | 2005-05-26 | 2006-11-30 | Hall Gerald E Jr | Methods for isolation of nucleic acids |
US20070015191A1 (en) * | 2005-07-01 | 2007-01-18 | Promega Corporation | Network of buoyant particles for biomolecule purification and use of buoyant particles or network of buoyant particles for biomolecule purification |
DE102005047736B4 (en) * | 2005-09-29 | 2008-08-14 | Aj Innuscreen Gmbh | Method and system for isolating nucleic acids from any complex starting materials |
US8030034B2 (en) * | 2005-12-09 | 2011-10-04 | Promega Corporation | Nucleic acid purification with a binding matrix |
US20070190526A1 (en) * | 2006-02-16 | 2007-08-16 | Nexgen Diagnostics Llc | Methods of extracting nucleic acids |
WO2008085116A1 (en) * | 2007-01-10 | 2008-07-17 | Ge Healthcare Bio-Sciences Ab | Mult i -modal ion exchange chromotography resins |
US8308940B2 (en) | 2007-12-06 | 2012-11-13 | The Board Of Trustees Of The University Of Illinois | Chromatography devices and methods |
JP5540467B2 (en) * | 2008-01-21 | 2014-07-02 | Jnc株式会社 | Charged material recovery method and kit using magnetic fine particles surface-modified with temperature-responsive polymer having upper critical solution temperature |
WO2010033627A2 (en) | 2008-09-16 | 2010-03-25 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
KR101569832B1 (en) * | 2008-11-19 | 2015-11-18 | 삼성전자주식회사 | Method for separating genomic DNA and plasmid DNA from each other and kit for same |
US20100305219A1 (en) * | 2009-06-02 | 2010-12-02 | The Board Of Trustees Of The University Of Illinois | Emulsions and foams using patchy particles |
US8222397B2 (en) * | 2009-08-28 | 2012-07-17 | Promega Corporation | Methods of optimal purification of nucleic acids and kit for use in performing such methods |
US8039613B2 (en) | 2009-08-28 | 2011-10-18 | Promega Corporation | Methods of purifying a nucleic acid and formulation and kit for use in performing such methods |
EP2598223B1 (en) | 2010-07-30 | 2022-04-06 | EMD Millipore Corporation | Chromatography media and method |
JP2014511687A (en) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | Engineered nucleic acid delivery and formulation |
CA2839693A1 (en) | 2011-06-19 | 2012-12-27 | Abogen, Inc. | Devices, solutions and methods for sample collection |
EP2742152B1 (en) * | 2011-08-12 | 2017-04-12 | Qiagen GmbH | Method for isolating nucleic acids |
CA2863215C (en) | 2012-01-30 | 2021-05-04 | Exact Sciences Corporation | Modification of dna on magnetic beads |
KR102196230B1 (en) | 2012-09-17 | 2020-12-29 | 더블유.알. 그레이스 앤드 캄파니-콘. | Chromatography media and devices |
KR102240332B1 (en) | 2013-03-15 | 2021-04-14 | 아벨리노 랩 유에스에이, 인크. | Methods for improved isolation of genomic dna templates for allele detection |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
EP2983804A4 (en) * | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | Removal of dna fragments in mrna production process |
EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
EP3019619B1 (en) | 2013-07-11 | 2021-08-25 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
BR112016003919A2 (en) * | 2013-08-05 | 2019-01-08 | Univ Johns Hopkins | MANUFACTURE OF HIERARCHICAL SILICA NANOMEMBRANES AND USES OF THE SAME FOR SOLID PHASE EXTRACTION OF NUCLEIC ACIDS |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
KR102293785B1 (en) | 2013-11-15 | 2021-08-26 | 아벨리노 랩 유에스에이, 인크. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
DK3114225T3 (en) * | 2014-03-07 | 2021-07-26 | Dna Genotek Inc | COMPOSITION AND PROCEDURE FOR STABILIZATION OF NUCLEIC ACIDS IN BIOLOGICAL SAMPLES |
PL3137209T3 (en) | 2014-05-02 | 2023-01-02 | W.R. Grace & Co. - Conn. | Functionalized support material and methods of making and using functionalized support material |
WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
AU2015289656A1 (en) | 2014-07-16 | 2017-02-16 | Modernatx, Inc. | Circular polynucleotides |
EP3230299A1 (en) | 2014-12-08 | 2017-10-18 | EMD Millipore Corporation | Mixed bed ion exchange adsorber |
US9422596B1 (en) * | 2015-04-27 | 2016-08-23 | Norgen Biotek Corp. | Methods and columns for nucleic acid purification |
ES2896897T3 (en) | 2015-06-05 | 2022-02-28 | Grace W R & Co | Clarifying agents for the bioprocessing of adsorbents and methods for producing and using the same |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
EP4036228A1 (en) | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Methods for the treatment of corneal dystrophies |
WO2017193097A1 (en) | 2016-05-06 | 2017-11-09 | Girihlet Inc. | Methods and compositions for determining specifc tcr and bcr chain pairings |
AU2018258580A1 (en) | 2017-04-28 | 2019-11-21 | Avellino Lab Usa, Inc. | Methods for detecting alleles associated with keratoconus |
EP3762491B1 (en) | 2018-03-03 | 2023-09-20 | Labcyte Inc. | Method for extracting a target moiety from a sample using acoustic droplet ejection |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2074892A (en) * | 1980-05-05 | 1981-11-11 | Varian Associates | Mixed phase chromatographic compositions |
US4523996A (en) * | 1984-02-22 | 1985-06-18 | Westinghouse Electric Corp. | Method of separating cationic from anionic beads in mixed resin beds |
WO1995006652A1 (en) * | 1993-08-30 | 1995-03-09 | Promega Corporation | Nucleic acid purification compositions and methods |
WO1995021179A1 (en) * | 1994-02-07 | 1995-08-10 | Qiagen Gmbh | Endotoxin reduction or removal process |
WO1996016186A1 (en) * | 1994-11-18 | 1996-05-30 | Thomas Jefferson University | Amplification based detection of bacterial infection |
WO1996036706A1 (en) * | 1995-05-19 | 1996-11-21 | Merck & Co., Inc. | A method for large scale plasmid purification |
WO1998031840A1 (en) * | 1997-01-21 | 1998-07-23 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4395271A (en) | 1979-04-13 | 1983-07-26 | Corning Glass Works | Method for making porous magnetic glass and crystal-containing structures |
US4297337A (en) | 1979-04-13 | 1981-10-27 | Corning Glass Works | Solid-phase immunoassays using magnetic glass |
US4233169A (en) | 1979-04-13 | 1980-11-11 | Corning Glass Works | Porous magnetic glass structure |
DE3211309A1 (en) | 1982-03-26 | 1983-09-29 | Metin Dipl.-Ing. 6100 Darmstadt Colpan | CHROMATOGRAPHIC METHOD FOR INSULATING MACROMOLECULES |
US4672040A (en) | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
US4695393A (en) | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5076950A (en) | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
DE3639949A1 (en) | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | METHOD FOR SEPARATING LONG CHAIN NUCLEIC ACIDS |
US4935342A (en) * | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
US4767670A (en) | 1987-01-21 | 1988-08-30 | E. I. Du Pont De Nemours And Company | Chromatographic supports for separation of oligonucleotides |
US5075430A (en) | 1988-12-12 | 1991-12-24 | Bio-Rad Laboratories, Inc. | Process for the purification of DNA on diatomaceous earth |
US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
US5523231A (en) | 1990-02-13 | 1996-06-04 | Amersham International Plc | Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules |
WO1992011933A1 (en) | 1991-01-04 | 1992-07-23 | Perseptive Biosystems, Inc. | Sulfonamide bonded hydrophilic coatings |
US5155018A (en) | 1991-07-10 | 1992-10-13 | Hahnemann University | Process and kit for isolating and purifying RNA from biological sources |
US5395498A (en) | 1991-11-06 | 1995-03-07 | Gombinsky; Moshe | Method for separating biological macromolecules and means therfor |
US5610274A (en) | 1991-11-20 | 1997-03-11 | Cpg, Inc. | Production and use of magnetic porous inorganic materials |
US5734020A (en) | 1991-11-20 | 1998-03-31 | Cpg, Inc. | Production and use of magnetic porous inorganic materials |
US5346994A (en) | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
US5316680A (en) | 1992-10-21 | 1994-05-31 | Cornell Research Foundation, Inc. | Multimodal chromatographic separation media and process for using same |
AT398973B (en) | 1992-11-18 | 1995-02-27 | Bonn Guenther Dr | METHOD FOR SEPARATING NUCLEIC ACIDS |
AU6230594A (en) | 1993-02-01 | 1994-08-29 | University Of Iowa Research Foundation, The | Quartenary amine surfactants and methods of using same in isolation of rna |
DE4307262A1 (en) | 1993-03-02 | 1994-09-08 | Christian Bergemann | Magnetic polymeric silicon dioxide |
US5990301A (en) | 1994-02-07 | 1999-11-23 | Qiagen Gmbh | Process for the separation and purification of nucleic acids from biological sources |
DK0743948T4 (en) | 1994-02-07 | 2004-02-02 | Qiagen Gmbh | Chromatographic isolation of nucleic acids |
US5582988A (en) | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
US5652348A (en) | 1994-09-23 | 1997-07-29 | Massey University | Chromatographic resins and methods for using same |
US5660984A (en) | 1994-12-09 | 1997-08-26 | Davis; Thomas E. | DNA isolating apparatus comprising a non-porous DNA binding, anion exchange resin and methods of use thereof |
DE19520398B4 (en) | 1995-06-08 | 2009-04-16 | Roche Diagnostics Gmbh | Magnetic pigment |
JP2965131B2 (en) | 1995-07-07 | 1999-10-18 | 東洋紡績株式会社 | Magnetic carrier for nucleic acid binding and nucleic acid isolation method using the same |
US5783686A (en) | 1995-09-15 | 1998-07-21 | Beckman Instruments, Inc. | Method for purifying nucleic acids from heterogenous mixtures |
SE9600590D0 (en) | 1996-02-19 | 1996-02-19 | Pharmacia Biotech Ab | Methods for chromatographic separation of peptides and nucleic acid and new high-affinity ion exchange matrix |
JPH09327291A (en) | 1996-06-11 | 1997-12-22 | Toyobo Co Ltd | Extraction and purification of rna |
JP3940935B2 (en) | 1996-06-11 | 2007-07-04 | 東洋紡績株式会社 | Extraction and purification method of plasmid DNA |
EP0961653B1 (en) | 1997-01-21 | 2002-12-11 | W.R. Grace & Co.-Conn. | Silica adsorbent on magnetic substrate |
-
1999
- 1999-05-14 US US09/312,139 patent/US6270970B1/en not_active Expired - Fee Related
-
2000
- 2000-05-12 CA CA002372521A patent/CA2372521C/en not_active Expired - Fee Related
- 2000-05-12 JP JP2000618447A patent/JP2002543980A/en not_active Ceased
- 2000-05-12 WO PCT/US2000/012954 patent/WO2000070041A1/en active IP Right Grant
- 2000-05-12 AU AU48415/00A patent/AU774810B2/en not_active Ceased
- 2000-05-12 AT AT00930626T patent/ATE272111T1/en not_active IP Right Cessation
- 2000-05-12 DE DE60012506T patent/DE60012506T2/en not_active Expired - Lifetime
- 2000-05-12 EP EP00930626A patent/EP1179056B1/en not_active Expired - Lifetime
-
2001
- 2001-07-24 US US09/912,045 patent/US6376194B2/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2074892A (en) * | 1980-05-05 | 1981-11-11 | Varian Associates | Mixed phase chromatographic compositions |
US4523996A (en) * | 1984-02-22 | 1985-06-18 | Westinghouse Electric Corp. | Method of separating cationic from anionic beads in mixed resin beds |
WO1995006652A1 (en) * | 1993-08-30 | 1995-03-09 | Promega Corporation | Nucleic acid purification compositions and methods |
WO1995021179A1 (en) * | 1994-02-07 | 1995-08-10 | Qiagen Gmbh | Endotoxin reduction or removal process |
WO1996016186A1 (en) * | 1994-11-18 | 1996-05-30 | Thomas Jefferson University | Amplification based detection of bacterial infection |
WO1996036706A1 (en) * | 1995-05-19 | 1996-11-21 | Merck & Co., Inc. | A method for large scale plasmid purification |
WO1998031840A1 (en) * | 1997-01-21 | 1998-07-23 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
Non-Patent Citations (2)
Title |
---|
BITNER, R. ET AL.: "Use of MagneSil(TM) paramagnetic particles for plasmid purification, PCR cleanup, and purification of dideoxy and big dye DNA sequencing reactions.", PROCEEDINGS OF SPIE - INT. SOC. OPT. ENG., vol. 3926, no. 3926, 2000, pages 126 - 33, XP000938886 * |
BROWN D M ET AL: "ANION-CATION SEPARATIONS ON A MIXED BED ALUMINA-SILICA COLUMN", JOURNAL OF CHROMATOGRAPHY,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 466, no. 1 + INDEX, 19 April 1989 (1989-04-19), pages 291 - 300, XP000026060, ISSN: 0021-9673 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691969B2 (en) | 1994-12-12 | 2014-04-08 | Life Technologies As | Isolation of nucleic acid |
US6914137B2 (en) | 1997-12-06 | 2005-07-05 | Dna Research Innovations Limited | Isolation of nucleic acids |
US8865405B2 (en) | 2001-11-28 | 2014-10-21 | Applied Biosystems Llc | Compositions and methods of selective nucleic acid isolation |
US9909118B2 (en) | 2006-10-10 | 2018-03-06 | Trovagene, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
EP2081442A4 (en) * | 2006-10-10 | 2010-11-10 | Trovagene Inc | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
EP2081442A2 (en) * | 2006-10-10 | 2009-07-29 | Xenomics, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
US9163229B2 (en) | 2006-10-10 | 2015-10-20 | Trovagene, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
WO2008045505A2 (en) | 2006-10-10 | 2008-04-17 | Xenomics, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
EP2757156A4 (en) * | 2011-09-13 | 2015-08-26 | Sony Corp | Nucleic acid purification method, nucleic acid extraction method, and nucleic acid purification kit |
US9498737B2 (en) | 2011-09-13 | 2016-11-22 | Sony Corporation | Method of purifying nucleic acids, method of extracting nucleic acids and kit for purifying nucleic acids |
US10023860B2 (en) | 2011-09-13 | 2018-07-17 | Sony Corporation | Method of purifying nucleic acids and kit for purifying nucleic acids |
WO2018215375A1 (en) * | 2017-05-22 | 2018-11-29 | General Electric Company | Improvements in the recovery of nucleic acids from solid supports |
US11891599B2 (en) | 2017-05-22 | 2024-02-06 | Qiagen Healthcare Biotechnologies Systems Gmbh | Recovery of nucleic acids from solid supports |
Also Published As
Publication number | Publication date |
---|---|
US6376194B2 (en) | 2002-04-23 |
EP1179056A1 (en) | 2002-02-13 |
ATE272111T1 (en) | 2004-08-15 |
CA2372521C (en) | 2009-09-08 |
JP2002543980A (en) | 2002-12-24 |
DE60012506T2 (en) | 2005-07-28 |
CA2372521A1 (en) | 2000-11-23 |
US20020001812A1 (en) | 2002-01-03 |
AU4841500A (en) | 2000-12-05 |
US6270970B1 (en) | 2001-08-07 |
EP1179056B1 (en) | 2004-07-28 |
AU774810B2 (en) | 2004-07-08 |
DE60012506D1 (en) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6270970B1 (en) | Mixed-bed solid phase and its use in the isolation of nucleic acids | |
US6806362B2 (en) | pH dependent ion exchange matrix and method of use in the isolation of nucleic acids | |
US6284470B1 (en) | Kits for cell concentration and lysate clearance using paramagnetic particles | |
US6194562B1 (en) | Endotoxin reduction in nucleic acid purification | |
AU771249B2 (en) | Method for purification and manipulation of nucleic acids using paramagnetic particles | |
JP2009118858A (en) | Cell concentration and lysate clearance using paramagnetic particles | |
AU2002225942B2 (en) | Lysate clearance and nucleic acid isolation using silanized silica matrices | |
EP1621618B1 (en) | Cell concentration and lysate clearance using paramagnetic particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 48415/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2372521 Country of ref document: CA Ref country code: CA Ref document number: 2372521 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 618447 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000930626 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000930626 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000930626 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 48415/00 Country of ref document: AU |